- Home
- MFIN vs AARD Comparison
MFIN vs AARD Comparison
Compare MFIN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | AARD |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.7M | 281.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MFIN | AARD |
|---|---|---|
| Price | $9.28 | $5.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $12.00 | ★ $19.63 |
| AVG Volume (30 Days) | 52.5K | ★ 377.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.78 | $4.74 |
| 52 Week High | $11.00 | $17.94 |
Technical Indicators
Market Signals| Indicator | MFIN | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 25.44 |
| Support Level | $9.25 | $4.74 |
| Resistance Level | $10.31 | $6.19 |
| Average True Range (ATR) | 0.29 | 0.52 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 7.63 | 7.81 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.